CytoMed Therapeutics Announces Promising Preclinical Results for Allogeneic γδ T Cell Therapy in Acute Myeloid Leukemia, Plans Clinical Trials in Southeast Asia
I'm PortAI, I can summarize articles.
CytoMed Therapeutics Ltd. announced promising preclinical results for its allogeneic γδ T cell therapy (CTM-GDT) for acute myeloid leukemia (AML), in collaboration with The University of Texas MD Anderson Cancer Center. The findings suggest that donor-derived γδ T cells could be a viable immunotherapy option for AML. The company plans to advance this therapy into clinical trials in Southeast Asia, while its lead product, CAR-γδ T cells (CTM-N2D), is currently in Phase 1 trials in Singapore.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments